Clinical, Not Real-World, Data is Still The Key To On- And Off-Label Reimbursement (Part 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
While payers have ever-more sophisticated datasets for observing drug use in the clinic, such information generally is “inconclusive” for reimbursement decisions, a managed care executive cautions.
You may also be interested in...
Preparing For Off-Label Drug Use In The Real World (Part 1 Of 2)
Plans are acquiring the tools to monitor and assess the risk/benefit of drug use outside of the approved indication. Smart companies are working with payers to understand their concerns around off-label use and the data requirements in support of it.
Pharma/Payor Deals An Important Step In The Shift To Value-Based R&D
Three major drug makers inked broad alliances with the research departments of major US payors in 2011. The alliances signal that even as pharma drug makers reorients its R&D engines to be more flexible and externally focused in the hopes of shedding risk and cost, such moves are not enough.
Insurers Call For Greater Transparency In Compendia Process
Third-party payers are looking for greater transparency in the processes that are used to generate compendia that list off-label uses of pharmaceuticals